

United States Fatent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

			**	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/429,694	10/27/1999	YONG WEI	TLC-144C-RIS	6218
21839 7	7590 12/12/2001			
BURNS DOANE SWECKER & MATHIS L L P			EXAMINER	
POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			KISHORE, GOLLAMUDI S	
			ART UNIT	PAPER NUMBER
			1615	

DATE MAILED: 12/12/2001

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/429,694

Gollamudi S. Kishore, Ph.D

Applicant(s)

Art Unit 1615

Wei

The MAILING DATE of this communication appear	s on the cover sheet with the correspondence address			
Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SE THE MAILING DATE OF THIS COMMUNICATION.	T TO EXPIRE <u>Three</u> MONTH(S) FROM			
 Extensions of time may be available under the provisions of 37 of after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) day 	ication.			
be considered timely.If NO period for reply is specified above, the maximum statutory communication.	period will apply and will expire SIX (6) MONTHS from the mailing date of this			
	by statute, cause the application to become ABANDONED (35 U.S.C. § 133). The mailing date of this communication, even if timely filed, may reduce any			
Status				
1) Responsive to communication(s) filed on <u>Aug 20,</u>	2001			
2a) ☑ This action is FINAL . 2b) □ This action	ction is non-final.			
3) Since this application is in condition for allowance closed in accordance with the practice under Ex p	except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims				
4) 💢 Claim(s) <u>1-57</u>	is/are pending in the application.			
4a) Of the above, claim(s)	is/are withdrawn from consideration.			
5) Claim(s)	is/are allowed.			
6) 💢 Claim(s) <u>1-57</u>	is/are rejected.			
7) Claim(s)	is/are objected to.			
8) Claims	are subject to restriction and/or election requirement.			
Application Papers				
9) \square The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/ar	re objected to by the Examiner.			
11) The proposed drawing correction filed on	is: a) \square approved b) \square disapproved.			
12) \square The oath or declaration is objected to by the Example 12.	niner.			
Priority under 35 U.S.C. § 119				
13) Acknowledgement is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d).			
a) \square All b) \square Some* c) \square None of:				
1. Certified copies of the priority documents ha	eve been received.			
2. Certified copies of the priority documents ha	eve been received in Application No			
3. Copies of the certified copies of the priority application from the International Bur *See the attached detailed Office action for a list of t				
14) Acknowledgement is made of a claim for domesti				
Attachment(s)	• •			
15) Notice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s).			
16) Notice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)			
17) Information Disclosure Statement(s) (PTO-1449) Paper No(s)				

Application/Control Number: 09/429,694

Art Unit: :1615

DETAILED ACTION

The amendment and the surrender of the patent dated 11-20-00 are acknowledged.

Page 2

1. Claims 16-57 are rejected under 35 U.S.C. 251 as being an improper recapture of broadened claimed subject matter patented in the parent application of the application for the patent upon which the present reissue is based. See *Hester Industries, Inc.* v. Stein, Inc., 142 F.3d 1472, 46 USPQ2d 1641 (Fed. Cir. 1998); In re Clement, 131 F.3d 1464, 45 USPQ2d 1161 (Fed. Cir. 1997); Ball Corp. v. United States, 729 F.2d 1429, 1436, 221 USPQ 289, 295 (Fed. Cir. 1984). A broadening aspect is present in the reissue which was not present in the application for patent. The record of the application for the patent shows that the broadening aspect (in the reissue) relates to subject matter that applicant previously patented prior to the prosecution of the application. Accordingly, the narrow scope of the claims in the patent was not an error within the meaning of 35 U.S.C. 251.

Applicant's arguments have been fully considered, but are not found to be persuasive. The patented file is a divisional of 08/383,291. The claims of 08/283,291 are drawn to compounds which read almost identically to the added claims in the reissue application, although some limitations are different. However, since there was a restriction requirement between the compound and liposome claims in the original application (see paper # 4) to try now to add claims in this application to the originally patented claims or

Art Unit: :1615

broadened counterparts is improper recapture as well as prohibited by the two year broadening rule.

The claims to specific cancers appears to be unsupported in the specification and such claims were not previously presented (only a general claim to cancer was presented before) and therefore, is improper broadening.

The declaration has been fully considered, but deemed to be insufficient since no error was pointed out specifically; only added claims are presented which by themselves do not define the error to be corrected.

- 4. In claim 1, line 11, the change made is still not underlined (now on line 13). 5. Claims 1-15 are allowable upon the correction of the claim as pointed out above.
- 1. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the Art Unit: :1615

advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *G.S. Kishore* whose telephone number is (703) 308-2440.

The examiner can normally be reached on Monday-Thursday from 6:30 A.M. to 4:00 P.M. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, T.K. Page, can be reached on (703)308-2927. The fax phone number for this Group is (703)305-3592.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [thurman.page@uspto.gov].

All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Art Unit: :1615

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703)308-1235.

Gollamudi S. Kishore, Ph. D

Primary Examiner

Group 1600

gsk

December 12, 2001